Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

209.93 -6.66 (-3.07%)

Streaming Delayed Price Updated: 11:33 AM EDT, Sep 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 11, 2026

One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.

Via The Motley Fool

Topics Intellectual Property

Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 10, 2026

Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.

Via The Motley Fool

Topics Intellectual Property

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 29, 2026

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

Via The Motley Fool

Axsome Therapeutics (NASDAQ:AXSM) Q1 Revenue Beat Misses Estimates as Launch Costs Surge ↗

May 04, 2026

Via Chartmill

Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run ↗

August 23, 2026

The company has also crushed broader equities over the past five years.

Via The Motley Fool

Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years ↗

August 17, 2026

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 46.84% on an annualized basis producing an average annual return of 58.59%. Currently, Axsome Therapeutics has a...

Via Benzinga

If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today ↗

August 13, 2026

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 26.64% on an annualized basis producing an average annual return of 40.19%. Currently, Axsome Therapeutics has a...

Via Benzinga

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results ↗

August 11, 2026

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.

Via Benzinga

Axsome Therapeutics Q2 Earnings Call Highlights ↗

August 10, 2026

Axsome Therapeutics (NASDAQ:AXSM) reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for...

Via MarketBeat

Topics Earnings

Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does ↗

August 04, 2026

These innovative biotech companies should reap the benefits of their breakthroughs.

Via The Motley Fool

3 Under-the-Radar Stocks to Buy and Hold ↗

July 10, 2026

Sometimes, little-known stocks are worth buying.

Via The Motley Fool

Better Growth Buy: Axsome vs Revolution Medicines ↗

July 09, 2026

These stocks both scored a win in the first half of the year.

Via The Motley Fool

Topics Artificial Intelligence

These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More ↗

July 06, 2026

These stocks have jumped in the double- and triple-digits.

Via The Motley Fool

Topics Artificial Intelligence Economy Stocks

Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say. ↗

July 02, 2026

The stock has soared more than 220% in three years.

Via The Motley Fool

3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗

June 16, 2026

All three could become highly prominent biotech companies within 10 years.

Via The Motley Fool

Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline ↗

June 06, 2026

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive...

Via MarketBeat

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗

May 24, 2026

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.

Via The Motley Fool

Topics Regulatory Compliance

Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch ↗

May 12, 2026

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation while continuing to expand its push in major depressive...

Via MarketBeat

3 Stocks Poised to Disrupt the Healthcare Market by 2030 ↗

May 08, 2026

The old healthcare model is breaking down.

Via The Motley Fool

Topics Artificial Intelligence

3 Overlooked Stocks Set to Soar in 2026 ↗

May 05, 2026

These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.

Via The Motley Fool

Why Did Axsome Therapeutics Stock Hit Another Record High Today? ↗

May 04, 2026

Investors think a new addition to the biotech's pipeline could be the next catalyst.

Via The Motley Fool

Axsome (AXSM) Q1 2026 Earnings Call Transcript ↗

May 04, 2026

Axsome (AXSM) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Axsome (AXSM) Q2 2025 Earnings Transcript ↗

May 04, 2026

Axsome (AXSM) Q2 2025 Earnings Transcript

Via The Motley Fool

Axsome (AXSM) Q1 2025 Earnings Call Transcript ↗

May 04, 2026

Axsome (AXSM) Q1 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Why Axsome Therapeutics Stock Jumped Over 20% in April ↗

May 02, 2026

Axsome shares reached an all-time high last month, and there might be more to come.

Via The Motley Fool

Is This Healthcare Stock a Millionaire Maker? ↗

April 08, 2026

If it can establish itself as a leading biotech in the future, it might be.

Via The Motley Fool

Topics Initial Public Offering Intellectual Property

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now ↗

March 25, 2026

The next 10 months might be challenging for this biotech.

Via The Motley Fool

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗

March 18, 2026

Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.

Via The Motley Fool

2 Under-the-Radar Stocks to Buy and Hold ↗

March 10, 2026

These biotechs are slowly making a name for themselves.

Via The Motley Fool

Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision ↗

March 09, 2026

This CNS drug developer with a diverse pipeline just saw a key insider trim their stake, according to recent filings.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.